The CEO of the Health Tech Alliance has described the decision not to include any new technologies in the 23/24 MedTech Funding Mandate as disappointing.
The NHS has instead asked systems to “prioritize the appropriate adoption of 2021/22 and 2022/23 technologies where this has not yet occurred,” adding that the technologies offer cost savings and improved patient outcomes and experiences.
It says that this decision will not overburden the sector while it continues to recover from the impacts of COVID-19 and continues to embed integrated care systems and the new commissioning relationships which underpin system working.
Nicholas Lansman, founder and CEO of the Health Tech Alliance, said: “The decision not to add any additional medical technologies to the 23/24 MedTech Funding Mandate is very disappointing. While it is important that the 22/23 technologies are properly implemented across the new ICS structure, this decision slams the door shut on new innovations being supported effectively across the NHS. It undermines the need to improve innovation within the health system and this will harm patient outcomes.”
You can read the full decision from NHS England here.
.